

[Calcium folinate \(leucovorin calcium\)](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [V03AF03](#)

EMLc

Indication

Osteosarcoma of bone and articular cartilage of unspecified sites ICD11 code: [2C21.Z](#)

INN

Calcium folinate

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule ; 7.5 mg per mL in 2 mL ampoule ; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg ; 5 mg ; 25 mg

EML status history

First added in 1979 ([TRS 641](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Calcium folinate \(leucovorin calcium\)](#)

DrugBank

[Calcium folinate \(Leucovorin\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of calcium folinate (Injection: 7.5 mg/mL in 2 mL ampoule; 10 mg/mL in 5 mL ampoule) to the EML and EMLc.